High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain whether a tumor is suitable for in vivo somatostatin receptor targeting, its somatostatin receptor expression has to be determined. There are specific indications for use of immunohistochemistry for the somatostatin receptor subtype 2A, but this has up to now been limited by the lack of an adequate reliable antibody. The aim of this study was to correlate immunohistochemistry using the new monoclonal anti-somatostatin receptor subtype 2A antibody UMB-1 with the gold standard in vitro method quantifying somatostatin receptor levels in tumor tissues. A UMB-1 immunohistochemistry protocol was developed, and tumoral UMB-1 staining levels were compared with somatostatin receptor binding site levels quantified with in vitro 125 I-[Tyr 3 ]octreotide autoradiography in 89 tumors. This allowed defining an immunohistochemical staining threshold permitting to distinguish tumors with somatostatin receptor levels high enough for clinical applications from those with low receptor expression. The presence of >10% positive tumor cells correctly predicted high receptor levels in 95% of cases. In contrast, absence of UMB-1 staining truly reflected low or undetectable somatostatin receptor expression in 96% of tumors. If 1% to 10% of tumor cells were stained, a weak staining intensity was suggestive of low somatostatin receptor levels. This study allows for the first time a reliable recommendation for eligibility of an individual patient for in vivo somatostatin receptor targeting based on somatostatin receptor immunohistochemistry. Under optimal methodological conditions, UMB-1 immunohistochemistry may be equivalent to in vitro receptor autoradiography.
S omatostatin receptors represent molecular tumor targets of increasing clinical importance. 17 They are highly expressed particularly in neuroendocrine tumors of the gastroenteropancreatic tract. This allows radiologic visualization of these tumors with high specificity and sensitivity with somatostatin analogues labeled with 111 In, such as OctreoScan, or 68 Ga, which is used for 68 Ga-DOTATOC positron-emission tomography/computer tomography. 5, 10, 12 This represents an important tool for patient staging and follow-up. Moreover, the same tumors can be subjected to peptide receptor radionuclide therapy with somatostatin analogues coupled with toxic nuclides such as 90 Y or 177 Lu in specialized centers. 11 Although often several of the 5 somatostatin receptor subtypes sst1, sst2A, sst3, sst4, and sst5 are concomitantly present in neuroendocrine tumors, sst2A is most important, as it shows the highest expression. 26 Correspondingly, the somatostatin analogues applied in clinical practice display highest affinity for this subtype. 22 An important prerequisite for successful in vivo somatostatin receptor targeting for imaging or therapeutic purposes is a high tumoral somatostatin receptor expression. Therefore, somatostatin receptor levels in an individual patient's tumor have to be determined to decide whether he or she is eligible for these applications. This can be achieved with either in vivo or in vitro methods. Tumoral somatostatin receptors can be measured directly in vivo by performing a preoperative OctreoScan or 68 Ga-DOTATOC positron-emission tomography/computer tomography. This approach has the following advantages: the entire tumor mass is evaluated; and the necessary radiotherapeutic tracer dose can be calculated. A preoperative scan is, however, not performed when it is not easily available or when the diagnosis of a neuroendocrine tumor is not suspected. Then, the somatostatin receptor expression has to be measured in vitro in the resected tumor tissue. The gold standard method to do this is in vitro somatostatin receptor autoradiography. It represents the in vitro correlate of an in vivo scan, as receptor binding sites are assessed with the same somatostatin analogues used in vivo. 10 Moreover, it is highly sensitive and specific, and receptor levels can be quantified. Limitations of this method include the restricted availability in highly specialized laboratories and the dependence on frozen tissue, which is often not collected. An alternative is immunohistochemistry, which is widely available, fast, and cheap and can be performed on formalin-fixed, paraffin-embedded (FFPE) tissue and even retrospectively on archival material.
At present, only the sst2A is assessed with immunohistochemistry, as it shows by far the highest expression in tumors. However, the value of sst2A immunohistochemistry has been limited. Until recently, 2 acceptable anti-sst2A antibodies existed: the excellent and well-characterized but noncommercial R2-88 antibody (A. Schonbrunn, Houston, TX) 18 and the commercially available SS-800 antibody (Gramsch Laboratories, Schwabhausen, Germany). 27 Although these antibodies yield satisfactory sst2A staining, 9 they suffer from several drawbacks. First, they are polyclonal antibodies. Therefore, they display heterogeneity from batch to batch. The excellent and extensively used R2-88 originates from an animal that died almost 2 decades ago. Although it has been possible to successfully detect sst2A receptors with R2-88 in a variety of normal and tumor tissues for >10 years, 8, 9, 18, 19, 24, 25 the quality of R2-88 immunohistochemistry for human tissue was found to strongly decline in recent times (B. Waser, M. Ko¨rner, A. Schonbrunn, and J.C. Reubi, unpublished data). Second, both antibodies show cross-reactivity with other antigens. 21 In summary, it has been difficult to establish a useful quantification scheme for staining results for these 2 antibodies that would allow reliable prediction of tumoral somatostatin receptor levels.
In recent times, a monoclonal anti-sst2A antibody, UMB-1, has become commercially available (Biotrend Chemikalien GmbH, Ko¨ln, Germany or Epitomics Inc., Burlingame, CA), and it exhibits considerably more effective and cleaner staining compared with polyclonal antisera. 4 The aim of this study was to test whether immunohistochemistry with this antibody may allow quantification of somatostatin receptor levels in tumor tissues and, therefore, whether it could be used as a reliable tool in routine diagnostics to evaluate tumoral sst2A expression. In particular, it was sought to develop a sensitive immunohistochemistry protocol and define a simple and easily applicable evaluation scheme for UMB-1 staining results that permits the selection of tumors with somatostatin receptor levels high enough for in vivo somatostatin receptor targeting. For this purpose, UMB-1 staining was compared with somatostatin receptor levels quantified with in vitro receptor autoradiography as reference method in 89 tumors. A retrospective study design was chosen because of the infrequency of the tumors of interest.
MATERIALS AND METHODS

Tumors
Eighty-nine tumors from 84 patients were studied. They are listed in Table 1 . They comprise tumor types with generally high somatostatin receptor levels, which are subjected to in vivo somatostatin receptor targeting in routine clinical practice or in clinical trials. Informed consent was available from all patients. The study conformed to the ethical guidelines of the Medical Faculty of the University of Berne and was reviewed by the Review Board of the Institute of Pathology.
All tumor samples were obtained from surgical resection specimens. In each case, an FFPE tissue block was available for sst2A immunohistochemistry and a frozen sample stored at À 801C for in vitro somatostatin receptor autoradiography. From the FFPE material, a tissue microarray (TMA) was additionally constructed, which was used to establish the UMB-1 immunohistochemistry protocol.
Sst2A Immunohistochemistry
Sst2A immunohistochemistry was performed on 4-mm-thick sections of FFPE tissue blocks with 2 different primary antibodies: the new monoclonal antibody UMB-1 (Biotrend) and the original noncommercial polyclonal antibody R2-88. 3, 7 For UMB-1 immunohistochemistry, different conditions were tested on the TMA, including a range of antibody concentrations (1:500 to 1:20) and various antigenretrieval methods [boiling in the pressure cooker in 10 mM citrate buffer (PC-C), pH 6.0, for 5 or 10 min; cooking in the microwave in 5% urea buffer, pH 9.0, or 10mM citrate buffer, pH 6.0, for 18 min; and digestion with 0.1% trypsin or 0.1% pronase]. R2-88 immunohistochemistry was carried out as described before with pretreatment in the microwave in 5% urea buffer, pH 9.0, and a concentration of 1:1000 of the primary antibody. 9 The tissue sections were incubated with the primary antibodies overnight at room temperature. As secondary antibody, a biotinylated goat anti-rabbit immunoglobulin was used. Antibody binding was visualized with the ABComplex/HRP (DAKO, Zug, Switzerland). Staining was performed with diaminobenzidine and counterstaining with hemalum. In each experiment, a well-characterized gastroenteropancreatic neuroendocrine tumor was included as positive control. In every case, antibody preabsorption with 100 nM of the immunogen peptide was performed as negative control for both R2-88 and UMB-1 immunohistochemistry.
Analysis of Immunohistochemical Staining
The immunohistochemical staining results were semiquantitatively assessed. Only membranous staining was considered. The proportion of stained tumor cells was expressed in percentages with increments of 10 (ie, 0%, 1% to 10%, 11% to 20% and so on of tumor cells stained). The staining intensity was analyzed using the following scoring system and as depicted in Figure 1 : 1+ = faint staining at Â 100 magnification; 2+ = strong staining at Â 100 magnification, not the entire circumference of tumor cell membranes stained at Â 400 magnification; and 3+ = strong staining at Â 100 magnification, the entire circumference of tumor cell membranes stained at Â 400 magnification (adapted from 13, 28 ).
Western Blot Analysis
Western blot analysis was performed on 5 tumors, 4 with and 1 without somatostatin receptor expression, on the basis of in vitro somatostatin receptor autoradiography. The procedure was carried out as published previously, 9 using a UMB-1 antibody concentration of 1:200.
In Vitro Somatostatin Receptor Autoradiography
In vitro somatostatin receptor autoradiography was carried out as described before. 20 In brief, 20-mm-thick cryostat sections were incubated with the sst2A-preferring radioligand 125 I-[Tyr 3 ]-octreotide for 2 hours at room temperature. Nonspecific binding was assessed by incubating serial tissue sections with the radioligand in the presence of 10 À 6 M of unlabeled octreotide. The slides were then exposed to Kodak films Biomax MR for 7 days at 41C. Radioligand binding to the tumors was analyzed in correlation with morphology using a corresponding neuroendocrine carcinoma of the gall bladder, C: pulmonary carcinoid tumor). A, 3+ staining intensity represents strong staining at low magnification and fully circumferential staining of tumor cell membranes at high magnification (inset). B, 2+ staining intensity equals strong staining at low magnification but no staining of the entire tumor cell circumference at high magnification (inset). C, 1+ staining intensity is defined by weak staining of the tumor cell membranes at low and high (inset) magnification.
hematoxylin and eosin-stained tissue section. The somatostatin receptor binding site density was measured using tissue standards containing known amounts of isotope and cross-calibrated to tissue-equivalent ligand concentrations, 2,14 as well as a computer-assisted imaging system (Interfocus, Mering, Germany).
Statistical Evaluation
Linear regression analysis and the Spearman rankcorrelation coefficient r 2 were used to correlate immunohistochemistry and autoradiography results. P<0.05 was considered to be statistically significant.
RESULTS
Immunohistochemical sst2A staining with the UMB-1 antibody was tested on a TMA under different experimental conditions to identify the optimal antigenretrieval method and antibody concentration. Heat pretreatment either using PC-C for 10 minutes or in the microwave in urea buffer (MW-U) yielded the best results: a large fraction of autoradiographically positive tumors were stained, and there was a distinct membranous staining of tumor cells and negligible cytoplasmatic background staining. PC-C appeared to be slightly superior to MW-U. Of the 95 evaluable spots in the TMA expected to be positive on the basis of somatostatin receptor autoradiography, a maximum of 78 (82%) could be stained with PC-C as compared with 76 (80%) with MW-U. Moreover, pretreatment with PC-C often resulted in staining of a larger fraction of tumor cells compared with pretreatment with MW-U, whereas the staining intensity was comparable. The other tested antigen-retrieval methods were unsatisfactory, staining only a small fraction of tumors expected to be positive. Relatively high UMB-1 concentrations had to be applied for optimal staining results. A concentration of 1:20 was found to be most appropriate: it stained a maximum of 78 of the 95 evaluable positive spots (82%) compared with a 1:100 concentration, which stained only 65 spots (68%) using PC-C pretreatment.
Several lines of evidence were provided for the specificity of UMB-1 staining for sst2A. First, antibody binding to the tumor cells was completely abolished by preabsorption with the immunogen peptide. Second, all but 1 of the 26 evaluable spots in the TMA expected to be negative on the basis of receptor autoradiography were not stained. Finally, UMB-1 Western blot analysis of somatostatin receptor-expressing tumors yielded a single specific band, which migrated at the expected molecular weight and was completely preabsorbed with the corresponding immunogen peptide (Fig. 2 ). UMB-1 Western blots gave congruent results with immunohistochemistry and receptor autoradiography in all studied tumors.
Immunohistochemistry for sst2A using PC-C pretreatment and a UMB-1 concentration of 1:20 was performed on large tissue sections of the 89 tumors. Results were semiquantitatively evaluated and compared with those of in vitro receptor autoradiography as the reference method. There was a good correlation of the results obtained with these 2 methods, as shown in There is a single broad band (arrow) migrating at approximately 53 kb, the expected size of sst2A. This band is completely abolished when adding the immunogen peptide. ]-octreotide binding density in the same tumor. Tumors with strong radioligand binding usually showed widespread and strong immunohistochemical staining as well (cases 1 and 2 of Fig. 4 ), whereas tumors with low autoradiographic receptor expression often displayed only weak UMB-1 staining in a few tumor cells (case 3 of Fig. 4 ). Statistically, the r 2 values for the associations between autoradiographic 125 I-[Tyr 3 ]-octreotide binding density on the one hand and the proportions of immunohistochemically positive tumor cells and staining intensities on the other hand were 0.464 (P<0.0001) and 0.428 (P<0.0001), respectively. We then analyzed how far UMB-1 immunohistochemistry was able to select tumors expressing enough somatostatin receptors for in vivo somatostatin receptor targeting. For this purpose, the tumors were divided into those with high autoradiographic receptor binding site levels anticipated to yield a positive in vivo scan and those with undetectable or low levels of receptor binding sites expected to result in a negative scan. A 125 I-[Tyr 3 ]-octreotide binding density of at least 3500 dpm/mg was considered to be necessary for an unambiguously positive scan, on the basis of previous comparative data. 10, 23 As apparent in Figures 3A and B and Table 2 , most tumors with high autoradiographic receptor levels showed a specific membranous UMB-1 staining in >10% of tumor cells and with an intensity of 2+ or 3+, whereas the majority of tumors with undetectable or low autoradiographic receptor expression exhibited <10% stained tumor cells and a weak staining intensity of 1+. The statistical performances of the cutoff levels of >10% stained tumor cells and >1+ staining intensity to identify tumors with a high somatostatin receptor expression are summarized in Table 3 . A cutoff level of 10% UMB-1positive tumor cells was excellent in predicting 125 I-[Tyr 3 ]octreotide binding density above 3500 dpm/mg, as only 2 of the 45 cases with >10% stained tumor cells exhibited a low autoradiographic receptor expression (positive predictive value of 95.4%). These 2 tumors showed relatively high 125 I-[Tyr 3 ]-octreotide binding levels between 2000 and 3000 dpm/mg. In contrast, only 2 of the 39 cases with low or undetectable 125 I-[Tyr 3 ]-octreotide binding displayed >10% stained tumor cells (specificity 95%). Forty-three of 50 cases with high autoradiographic receptor levels were correctly identified with this cutoff level, resulting in a sensitivity of 86%. The negative predictive value amounted to 84%: 7 of the 44 cases with 0% to 10% stained tumor cells showed high somatostatin receptor levels by autoradiography. In comparison, the cutoff level of >1+ staining intensity exhibited a higher sensitivity (96%) and a higher negative predictive value (94%). The best negative predictive value was obtained when looking for the absence of any immunohistochemical staining: if there was no staining at all, the likelihood of low autoradiographic receptor levels was 96%. Only 1 single case with negative immunohistochemistry, a serotonin-producing tumor, showed a discrepant high 125 I-[Tyr 3 ]-octreotide binding.
Only a small fraction of cases was misdiagnosed with the cutoff levels of >10% tumor cells with UMB-1 staining and of >1+ UMB-1 staining intensity. This included in particular 7 tumors with <10% UMB-1positive tumor cells but with very high autoradiographic somatostatin receptor levels (Fig. 3A) . It is noteworthy that in 2 of these cases (namely, meningiomas) there was indeed a strong UMB-1 staining present, which was, however, not clearly membranous but rather indistinct. An example is depicted in Figure 5 in the top row. This tumor displays strong immunohistochemical UMB-1 staining in the vast majority of tumor cells but in <10% of tumor cells in a clearly membranous distribution. Autoradiographically, the tumor exhibits very high somatostatin receptor levels, which appear to originate from a larger fraction of tumor cells than from only those with membranous staining. Could assessment of UMB-1 staining intensity be helpful in the differentiation between low and high tumoral somatostatin receptor levels in tumors with <10% stained cells? Indeed, a 1+ staining intensity was preferably present in cases with low 125 I-[Tyr 3 ]-octreotide binding site levels, whereas 2+ and 3+ staining intensities equally occurred in tumors with low and high autoradiographic receptor amounts (Fig. 3A) .
Furthermore, a small proportion (14%) of tumors with 2+ or 3+ staining intensity exhibited only low 125 I-[Tyr 3 ]-octreotide binding site levels <3500 dpm/mg or even completely negative results on autoradiography (Fig. 3B ). It is interesting to note that in all but one of these tumors <10% of tumor cells were stained. A typical example is shown in Fig. 5 tumor cells were strongly stained with UMB-1, comprising, however, only a small part of the tumor, whereas the poorly differentiated neuroblastic tumor cells were negative for UMB-1. Receptor autoradiography results were completely negative. Finally, it was assessed how variations of the experimental conditions and the use of different antibodies could affect the ability of immunohistochemistry to select tumors with a high autoradiographic somatostatin receptor expression. This is shown in Table 2 . For UMB-1 immunohistochemistry, the 2 best antigen-retrieval methods, PC-C and MW-U, were compared. It was confirmed that with pretreatment with PC-C slightly more tumoral staining is obtained, with more tumors exhibiting >10% stained cells or a staining intensity of >1+. In contrast, when comparing UMB-1 with the original anti-sst2A antibody R2-88, the latter failed to stain a considerably larger fraction of tumors with high autoradiographic somatostatin receptor levels, namely, 20% as opposed to 4%.
DISCUSSION
The study shows that immunohistochemistry using the newly available monoclonal antibody UMB-1 is excellent and at present the best available tool for the semiquantitative characterization of tumoral sst2A expression in FFPE tissues. It is highly specific, and a very clean and easily identifiable membranous staining pattern can be obtained. Moreover, UMB-1 staining levels correlate well with tumoral somatostatin receptor binding site amounts as measured with in vitro receptor autoradiography, the in vitro correlate of in vivo receptor imaging. In fact, the first evaluation scheme of sst2A immunohistochemistry is proposed, which reliably selects tumors with high somatostatin receptor expression suitable for in vivo somatostatin receptor targeting and which, moreover, is simple and easy to apply. The presence of >10% of tumor cells stained with UMB-1 correctly predicted high somatostatin receptor levels in over 95% of cases. In contrast, no staining truly reflected low or undetectable somatostatin receptor expression in 96% of tumors. UMB-1 immunohistochemistry is thus equivalent to analogous tests for molecular targets in paraffin-embedded tissues such as the HercepTest in breast cancer. 15 Only a few limitations of this semiquantitative evaluation of UMB-1 immunohistochemistry exist that have to be recognized. These include the dependence on a good immunohistochemical procedure, interpretational pitfalls, and the possibility of selecting false-negative or false-positive cases.
The usefulness of sst2A immunohistochemistry for tumor diagnostics strongly depends on a good antibody and an optimal technical procedure. UMB-1, at present the only commercially available monoclonal antibody against sst2A, was found to show the best staining characteristics in comparison with other reference antibodies. It produced the clearest membranous staining and virtually no cytoplasmatic background staining in a large proportion of somatostatin receptor-positive cases. In accordance with our observations, UMB-1 had initially been demonstrated to yield significantly more effective and cleaner staining compared with polyclonal antisera. 4 Moreover, UMB-1 shows all advantages of a monoclonal antibody, such as no variation from batch to batch and unlimited supply. In contrast, SS-800 (the only other appropriate commercial anti-sst2A antibody) and the noncommercial R2-88 antibody (up to now the gold standard antibody for sst2A immunohistochemistry) exhibit less distinct membranous and more diffuse cytoplasmatic background staining, as reported previously. 9 Moreover, R2-88 showed in the present series significantly weaker tumor staining compared with previous studies 9, 18, 19 and compared poorly with UMB-1. For many years, R2-88 (generated in the early 1990s) permitted the successful characterization of sst2A receptors in a variety of tissues 8, 9, 18, 19, 24, 25 but is likely to have lost its good performance for immunohistochemistry in recent times. Also, the choice of the antigen-retrieval method has an important effect on immunohistochemical sst2A detection. In our hands, best staining results were obtained with selected heat pretreatments. Although only negligible differences in overall excellent staining were observed between cooking in a pressure cooker (pH 6.0) for 10 minutes and boiling in a microwave (pH 9.0), a significantly poorer result was obtained using the citrate buffer for microwave boiling or protease digestion. Importantly, all pretreatment methods yielded positive results in some samples, but the rate of false-negative stainings increased markedly under suboptimal pretreatments.
To determine how immunohistochemistry can identify tumors with high somatostatin receptor expression (the prerequisite for successful in vivo somatostatin receptor targeting), UMB-1 staining results needed to be correlated with levels of the actual clinical target, that is, the receptor binding sites. The latter can be measured with 2 established methods, either in vivo with a somatostatin receptor scan or in vitro with receptor autoradiography. There is a good correlation between results obtained by in vivo somatostatin receptor scan and in vitro somatostatin receptor autoradiography, based on previous investigations 6, 10 and own experience of >2 decades. For this study, in vitro receptor autoradiography was chosen as the reference method. It allowed determining with high specificity and selectivity somatostatin receptor expression in tumor cells, as it can be correlated with morphology and controlled for nonspecific radioligand binding by displacement experiments with a cold somatostatin analogue. In contrast, a positive in vivo scan may not always be tumor specific. Possible tracer uptake in tissues other than tumor cells, either specifically in somatostatin receptor-expressing physiological targets such as ectopic spleen or tumor-infiltrating leukocytes or nonspecifically in tumor necrosis or scars, cannot be distinguished. Moreover, not all tumors of diagnostic interest are well visible on an in vivo scan, depending on their location and size. Another important advantage of choosing receptor autoradiography was the possibility of being able to include tumors with low somatostatin receptor expression below the detection threshold of an in vivo scan. Only a few previous studies have compared the results of sst2A immunohistochemistry with tumoral somatostatin receptor binding site levels. The latter were always defined by an in vivo scan. In most of these series, the correlation was considerably worse than in the present one. 1, 13, 28 This can be probably largely explained by the use of the polyclonal anti-sst2A antibody SS-800, which shows poorer staining characteristics compared with UMB-1. The results of the single published investigation using UMB-1 are in agreement with the present findings 16 : Mü ssig and colleagues obtained a similar correlation between sst2A immunohistochemistry and somatostatin receptor binding site densities, with only slightly lower r 2 values. However, the sensitivity of immunohistochemistry for a positive scan was with 64% significantly lower. This may be explained by different immunohistochemical procedures (Mu¨ssig and colleagues used a lower antibody concentration and another antigenretrieval method), a different study population, or, theoretically, with a lower sensitivity of in vitro receptor autoradiography compared with an in vivo scan.
On the basis of the comparison with in vitro somatostatin receptor autoradiography, UMB-1 immunohistochemistry with an optimized technical procedure represents the most reliable in vitro method for FFPE material to identify tumors with high somatostatin receptor levels suitable for in vivo somatostatin receptor targeting. Only a small fraction of cases remain in which UMB-1 immunohistochemistry cannot correctly predict somatostatin receptor levels. In those few inconclusive cases, in vivo imaging or in vitro receptor autoradiography would be the solution of choice. Otherwise, underestimation of tumoral somatostatin receptors would exclude patients who would benefit from in vivo somatostatin receptor targeting. In the present series, 14% of tumors with high somatostatin receptor levels had only a small fraction of <10% of tumor cells stained with UMB-1. Various explanations for this false negativity can be discussed. Theoretically, some tumors may predominantly express large amounts of sst3 or sst5 that weakly bind octreotide but are not detected by sst2A immunohistochemistry. However, it was previously shown that expression of only sst2A, but not of other somatostatin receptor subtypes, correlated with octreotide binding. 1, 16 Alternatively, tumors may display a focal somatostatin receptor expression in only 1 of the different samples subjected to immunohistochemistry and receptor autoradiography. Furthermore, poor fixation of the FFPE material may significantly impair immunohistochemical sst2A staining. In fact, we have repeatedly observed UMB-1 staining only in peripheral but not in central zones, especially of large tumors. Another pitfall in the evaluation of tumoral UMB-1 staining is the poor membranous but rather blurred staining of meningiomas that actually express high sst2A levels. 26 This particular staining pattern of meningiomas is likely explained by the prominent interdigitation of intercellular membranes typical of meningioma tumor cells, which yields an indistinct cell membrane staining at the light microscopic level. In these few instances of minor diagnostic importance, the cytoplasmatic staining better reflects the actual somatostatin receptor levels and may well correspond to receptors located in the strongly interdigitated cell membrane.
In contrast, overestimation of tumoral somatostatin receptor levels by immunohistochemistry may also represent a diagnostic problem. In the present series, this occurred mainly when UMB-1 staining intensity alone was considered. In particular, in 4 of the 29 tumors (5%) that were completely negative by receptor autoradiography, strong (2+, 3+) tumor cell staining was present. Of importance, in all these cases, <10% of tumor cells were stained. It appears logical that high tumoral receptor levels allowing a positive in vitro or in vivo scan are the result not of only a few tumor cells that individually express a large number of receptors but also of a receptor expression in a substantial number of tumor cells in a larger area. This is illustrated with the example of the ganglioneuroblastoma. In this case, it is not surprising that the few sst2A-expressing ganglionic tumor cells are below the detection level of autoradiography, which is completely negative. It thus emerges that in the interpretation of immunohistochemical sst2A staining, priority should be given to the fraction of stained tumor cells over the staining intensity of individual cells. To obtain representative specificity values, >40% of the cases included in the study were tumors with autoradiographically undetectable or low somatostatin receptor expression. In only 5% of these cases was UMB-1 staining of >10% of tumor cells present.
The results obtained by comparing the excellent UMB-1 immunohistochemistry with tumoral in vitro 125 I-[Tyr 3 ]-octreotide binding site levels allow new recommendations for the use of sst2A immunohistochemistry in daily diagnostics for an optimally tailored patient management. These recommendations are provided in Table 4 . Table 4 also proposes an interpretation of the staining results regarding the suitability of individual tumors for in vivo somatostatin receptor targeting. It is noteworthy that the cutoff level of 10% stained tumor cells is based on the experimental conditions in our laboratory. Cutoff staining levels may vary from laboratory to laboratory, depending on the sensitivity of the immunohistochemical procedure applied. To know the performance of an individual immunohistochemical test, an interlaboratory comparison on a reference set of cases with known somatostatin receptor binding site levels defined by in vitro or in vivo binding methods may be helpful. The proposals in Table 4 may represent the current best option for a recommendation if an individual patient is eligible for in vivo somatostatin receptor targeting on the basis of somatostatin receptor immunohistochemistry.
In conclusion, UMB-1 immunohistochemistry may reach a sensitivity virtually equivalent to that of in vitro receptor autoradiography and may even replace autoradiography if the optimal methodological conditions are identified and an external quality control is performed. Assess only membranous staining Assess percentage of stained tumor cells Assess staining intensity (according to Fig. 1 )
Interpretation of results
If >10% tumor cells are stained, the tumor is very likely to express high somatostatin receptor levels that would allow successful in vivo somatostatin receptor targeting If 1%-10% of tumor cells are stained, it is inconclusive whether enough receptors for in vivo somatostatin receptor targeting are present. A weak staining intensity in these cases is, however, suggestive of too low somatostatin receptor levels If there is no tumor cell staining at all, the tumor is likely to not express enough somatostatin receptors for in vivo somatostatin receptor targeting
